Holen Sie sich die Stockscreener-App
10.83
3.04%
0.32
Schlusskurs vom Vortag:
$10.51
Offen:
$10.49
24-Stunden-Volumen:
689.13K
Relative Volume:
0.83
Marktkapitalisierung:
$618.77M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-4.0714
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+1.21%
1M Leistung:
+6.49%
6M Leistung:
+142.28%
1J Leistung:
+49.59%
1-Tages-Spanne:
$10.30
$10.88
1-Wochen-Bereich:
$10.30
$11.50
52-Wochen-Spanne:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
10.83 | 600.49M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockGlobal Markets & Safe Capital Investment Plans - BỘ NỘI VỤ
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan
4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada
[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan
4D Molecular Therapeutics Executive Sells Shares - TradingView
Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView
Published on: 2025-11-19 17:30:27 - newser.com
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN
What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView
FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com
4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks
4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus
4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail
4D Molecular Therapeutics Appoints New CFO - TradingView
4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer | FDMT Stock News - Quiver Quantitative
[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
FY2025 Earnings Forecast for FDMT Issued By Chardan Capital - MarketBeat
Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
4DMT Announces New Employment Inducement Grants - Enidnews.com
4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan
Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks
Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st
Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq
4D Molecular Therapeutics Misses On Revenue But Secures New Funding - Finimize
Working capital per share of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
4D Molecular Therapeutics: Financial Backing Strengthens Clinical Pipeline Prospects - Ad-hoc-news.de
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):